Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
3186studies shown
Showing 2,276-2,300 of 3,186
CompletedNCT00001258

Studies of Frontal Lobe Brain Functioning in Schizophrenia

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 90 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
SuspendedNCT05046353

D-serine AudRem: R33 Phase

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 50 Years
Countries
United States
Sponsor
New York State Psychiatric Institute
Condition
Schizophrenia
CompletedNCT05893862

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

This study exists to better understand the safety of the medication MK-8189 and how manageable it feels in practice. Researchers are trying to understand how people respond to the medication MK-8189 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Merck Sharp & Dohme LLC
Condition
Schizophrenia
CompletedNCT02411695

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

This study exists to better understand the safety of a digital app or remote support tool and how manageable it feels in practice. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 13 Years to 17 Years
Countries
United States
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Condition
Schizophrenia
CompletedNCT00001486

Genetic Study of Schizophrenia

This study exists to explore whether the medication Schizophrenia could improve care and understanding. Researchers are trying to understand whether the medication Schizophrenia can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
RecruitingNCT05778591

Low-dose Buprenorphine as a Modulator of Social Motivation in Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
RecruitingNCT01730781

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand what smoking support or smoking-related treatment can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
RecruitingNCT06969755

Biomarkers to Enhance Early Schizophrenia Treatment

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand whether blood tests and biological markers can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
Canada, United States
Sponsor
Northwell Health
Condition
Schizophrenia
RecruitingNCT01409109

Database Registry for Neural Network Biomarkers in Psychosis

This study exists to learn from real-world information that can show how a digital app or remote support tool fits into care. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Texas Southwestern Medical Center
Condition
Schizophrenia
TerminatedNCT05724810

Deep rTMS Modulating Insula Synaptic Density and Smoking Behavior in Schizophrenia

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand what smoking support or smoking-related treatment could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
Stony Brook University
Condition
Schizophrenia
CompletedNCT05204407

Luteolin for the Treatment of People With Schizophrenia

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand whether blood tests and biological markers can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
SuspendedNCT05567848

Accelerated TMS in Psychosis

This study exists to understand whether a digital app or remote support tool is both safe enough and useful enough to take further. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Beth Israel Deaconess Medical Center
Condition
Schizophrenia
RecruitingNCT06947941

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

This study exists to explore whether this type of care could improve care and understanding. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 55 Years to 90 Years
Countries
Australia, Canada, Japan, United Kingdom, United States
Sponsor
Bristol-Myers Squibb
Condition
Schizophrenia
CompletedNCT00004571

Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 120 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
TerminatedNCT05211947

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

This study exists to explore whether a medication treatment could improve care and understanding. Researchers are trying to understand what a medication treatment could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 51 Years
Countries
Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT00942981

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

This study exists to see whether the medication NNC-112 can make care clearer and more responsive. Researchers are trying to understand whether the medication NNC-112 can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 90 Years
Countries
United States
Sponsor
National Institute of Mental Health (NIMH)
Condition
Schizophrenia
RecruitingNCT04226898

Synbiotic Compound to Reduce Symptoms of Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand what a digital app or remote support tool could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
Sheppard Pratt Health System
Condition
Schizophrenia
TerminatedNCT06155695

Auditory Control Enhancement (ACE) in Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 40 Years
Countries
United States
Sponsor
Brian A Coffman, PhD
Condition
Schizophrenia
RecruitingNCT04887792

Acetazolamide for Treatment Resistant Schizophrenia

This study exists to compare options and see whether a digital app or remote support tool offers something meaningfully different. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
India, United States
Sponsor
Vishwajit Nimgaonkar, MD PhD
Condition
Schizophrenia
SuspendedNCT05259306

Low-Intensity Focused Ultrasound Neuromodulation of the Mediodorsal Thalamus for Treatment-Resistant Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 21 Years to 80 Years
Countries
United States
Sponsor
NYU Langone Health
Condition
Schizophrenia
RecruitingNCT03971487

Ocrelizumab for Psychosis by Autoimmunity

This study exists to compare options and see whether this type of care offers something meaningfully different. Researchers are trying to understand what this type of care can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
United States
Sponsor
The Methodist Hospital Research Institute
Condition
Schizophrenia
CompletedNCT05345184

Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2

This study exists to see whether questionnaires and follow-up reports is workable and worth testing more broadly. Researchers are trying to understand whether questionnaires and follow-up reports can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Michigan
Condition
Schizophrenia
CompletedNCT05899348

iTEST: Introspective Accuracy as a Novel Target for Functioning in Psychotic Disorders

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
CompletedNCT05693935

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of TV-44749 in Adults With Schizophrenia

This study exists to understand whether the medication TV-44749 is both safe enough and useful enough to take further. Researchers are trying to understand how people respond to the medication TV-44749 in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Bulgaria, China, Romania, Turkey, United States
Sponsor
Teva Branded Pharmaceutical Products R&D LLC
Condition
Schizophrenia
CompletedNCT06627413

Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

This study exists to better understand the safety of this type of care and how manageable it feels in practice. Researchers are trying to understand how people respond to this type of care in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia